News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Xianchen Liu

Articles by Xianchen Liu

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Doris Makari,Rachel M. Layman,Hope S. Rugo, MD

August 20th 2024

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Rachel M. Layman,Hope S. Rugo, MD

April 28th 2023

49 Financial Toxicity Among Patients With Breast Cancer During the COVID-19 Pandemic

ByYan Wu,Xianchen Liu,Martine C. Maculaitis,Benjamin Li,Alexa Berk,Angelina Massa,Marisa C. Weiss,Lynn McRoy

April 26th 2023

18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19

ByMartine C. Maculaitis,Xianchen Liu,Alexandra Berk,Angelina Massa,Marisa C. Weiss,Samantha M. Kurosky,Benjamin Li,Lynn McRoy

May 6th 2022

6 Real-world Adherence and Persistence With Palbociclib Treatment Among Insured Patients With HR+/HER2– Metastatic Breast Cancer in the United States

ByNicole M. Engel-Nitz,Samantha M. Kurosky, Mary Grace Johnson,Michael P. Johnson,Xianchen Liu

April 18th 2022

Latest Updated Articles

6 Real-world Adherence and Persistence With Palbociclib Treatment Among Insured Patients With HR+/HER2– Metastatic Breast Cancer in the United States
Published: April 18th 2022 | Updated:
11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above
Published: April 28th 2023 | Updated:

Trending on CancerNetwork

Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma

Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC

Relacorilant Regimen Improves PFS in Platinum-Resistant Ovarian Cancer

FDA Issues CRL for Dasatinib in CML/ALL

Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC

© 2025 MJH Life Sciences^®

All rights reserved.